Table 4

Comparison of VTE management specific for patients with lung cancer among the latest ITAC,4 ASCO5 and ASH6 guidelines of cancer-associated VTE

ITACASCOASH
AssessmentNo mention of VTE risk assessment score specific for lung cancer. The Khorana score is recommended for pan-cancer patients.The COMPASS-CAT score performs better, compared with the Khorana score, for lung patients with cancer, although the latter is recommended for pan-cancer patients.No mention of VTE risk assessment score specific for lung cancer. The Khorana score is recommended for pan-cancer patients.
ThromboprophylaxisThromboprophylaxis reduces VTE incidence without improving OS for patients lung cancer. Primary thromboprophylaxis is not routinely recommended for patients with lung cancer.Thromboprophylaxis reduces VTE incidence without improving OS for patients with lung cancer.Thromboprophylaxis reduces VTE incidence and improves OS without increasing the bleeding risk or thrombocytopenia for patients with lung cancer.
TreatmentNo mention of VTE treatment specific for lung cancer. VTE treatment for patients with lung cancer follows the guidelines.No mention of VTE treatment specific for lung cancer. VTE treatment for patients with lung cancer follows the guidelines.No mention of VTE treatment specific for lung cancer. VTE treatment for patients with lung cancer follows the guidelines.
  • ASCO, American Society of Clinical Oncology; ASH, American Society of Hematology; ITAC, International Initiative on Thrombosis and Cancer; OS, overall survival; VTE, venous thromboembolism.